A new compound has been discovered by researchers which could potentially target the cause of type 2 diabetes, a study suggests.
Researchers at the Harvard T.H. Chan School of Public Health, Boston developed a drug-screening tool that allowed them to measure molecules supervising processes in the endoplasmic reticulum (ER). These molecules are known as chaperones.
The ER is a network of tubules that function during glucose metabolism, involving lipids and proteins. It has been known to researchers that stress of the ER is a key factor in diabetes and other diseases developing, such as cystic fibrosis and Alzheimer’s disease.
This is because insulin resistance occurs when the ER is stressed, which is a precursor of type 2 diabetes. As a result, the demand for new proteins and lipids cannot be kept up.
The researchers found that the compound azoramide protected cells during ER stress, as well as improving blood glucose levels in obese mice and mice with type 2 diabetes.
They suggested that azoramide increased the number of chaperones in the ER. This then led to insulin-producing beta cells functioning better and increased insulin sensitivity.
The Harvard team now aim to test azoramide in human clinical trials to assess if modulating the ER can lead to drug therapies for type 2 diabetes.
The findings from this study were published in the journal Science Translational Medicine.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…